AtaiBeckley Inc.

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

Helus Pharma Inc.PharmaceuticalsUnited States

66% match

Helus Pharma Inc. advances mental health treatments by developing novel, second-generation therapies, proprietary drug delivery systems, and patent-protected molecules. The company serves the healthcare and pharmaceutical sectors.

H LUNDBECK A/S H. LUNDBECK0ABR · PharmaceuticalsUnited Kingdom

64% matchPublic

H. Lundbeck A/S is a global pharmaceutical company that specializes exclusively in the research, development, and commercialization of therapies for brain diseases. It provides treatments for various neurological and psychiatric conditions, such as migraine, Parkinson's disease, Alzheimer's disease, depression, and schizophrenia, serving patients worldwide.

ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.

Beckley PsytechBiotechUnited States

76% matchAI 17/100Green 4/100

Beckley Psytech is a UK-based clinical-stage biotechnology company developing psychedelic medicines for psychiatric and neurological disorders. Its programs have included BPL-003, an intranasal formulation of 5-MeO-DMT, intended for conditions such as treatment-resistant depression and alcohol use disorder.